托珠单抗成功治疗视神经脊髓炎和特发性多中心Castleman病共发：1例报告

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Internal Medicine Pub Date : 2024-12-26 DOI:10.2169/internalmedicine.4503-24

Takuma Tsuzuki Wada, Kazuhiro Yokota, Mariko Okada, Takaya Ichimura, Takehito Ueno, Nobuhito Okumura, Iichiro Osawa, Kaiji Inoue, Yuji Akiyama, Yoshihiko Nakazato, Atsushi Sasaki, Toshimasa Yamamoto, Toshihide Mimura

{"title":"托珠单抗成功治疗视神经脊髓炎和特发性多中心Castleman病共发：1例报告","authors":"Takuma Tsuzuki Wada, Kazuhiro Yokota, Mariko Okada, Takaya Ichimura, Takehito Ueno, Nobuhito Okumura, Iichiro Osawa, Kaiji Inoue, Yuji Akiyama, Yoshihiko Nakazato, Atsushi Sasaki, Toshimasa Yamamoto, Toshihide Mimura","doi":"10.2169/internalmedicine.4503-24","DOIUrl":null,"url":null,"abstract":"We herein report a 52-year-old woman with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and idiopathic multicentric Castleman disease (iMCD) who was successfully treated with tocilizumab, a humanized anti-human interleukin (IL)-6 receptor monoclonal antibody. This is the first report of a case of coexisting NMOSD and iMCD. IL-6 is involved in the pathogenesis of both NMOSD and iMCD, and tocilizumab is effective against both diseases. By treating the patient with tocilizumab, the lung lesions due to iMCD improved, and the neurological symptoms of NMOSD did not recur.","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Co-occurrence of Neuromyelitis Optica Spectrum Disorder and Idiopathic Multicentric Castleman Disease Successfully Treated with Tocilizumab: A Case Report.\",\"authors\":\"Takuma Tsuzuki Wada, Kazuhiro Yokota, Mariko Okada, Takaya Ichimura, Takehito Ueno, Nobuhito Okumura, Iichiro Osawa, Kaiji Inoue, Yuji Akiyama, Yoshihiko Nakazato, Atsushi Sasaki, Toshimasa Yamamoto, Toshihide Mimura\",\"doi\":\"10.2169/internalmedicine.4503-24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We herein report a 52-year-old woman with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and idiopathic multicentric Castleman disease (iMCD) who was successfully treated with tocilizumab, a humanized anti-human interleukin (IL)-6 receptor monoclonal antibody. This is the first report of a case of coexisting NMOSD and iMCD. IL-6 is involved in the pathogenesis of both NMOSD and iMCD, and tocilizumab is effective against both diseases. By treating the patient with tocilizumab, the lung lesions due to iMCD improved, and the neurological symptoms of NMOSD did not recur.\",\"PeriodicalId\":13719,\"journal\":{\"name\":\"Internal Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-12-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Internal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2169/internalmedicine.4503-24\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2169/internalmedicine.4503-24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

我们在此报告一位患有抗水通道蛋白4抗体阳性的视神经脊髓炎谱系障碍（NMOSD）和特发性多中心Castleman病（iMCD）的52岁女性，她成功地接受了tocilizumab（一种人源化的抗人白细胞介素(IL)-6受体单克隆抗体）的治疗。这是首次报告NMOSD和iMCD共存的病例。IL-6参与了NMOSD和iMCD的发病机制，托珠单抗对这两种疾病都有效。通过tocilizumab治疗患者，iMCD引起的肺部病变得到改善，NMOSD的神经系统症状没有复发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Co-occurrence of Neuromyelitis Optica Spectrum Disorder and Idiopathic Multicentric Castleman Disease Successfully Treated with Tocilizumab: A Case Report.

We herein report a 52-year-old woman with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and idiopathic multicentric Castleman disease (iMCD) who was successfully treated with tocilizumab, a humanized anti-human interleukin (IL)-6 receptor monoclonal antibody. This is the first report of a case of coexisting NMOSD and iMCD. IL-6 is involved in the pathogenesis of both NMOSD and iMCD, and tocilizumab is effective against both diseases. By treating the patient with tocilizumab, the lung lesions due to iMCD improved, and the neurological symptoms of NMOSD did not recur.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Internal Medicine 医学-医学：内科

CiteScore

1.90

自引率

8.30%

发文量

审稿时长

2.2 months

期刊介绍： Internal Medicine is an open-access online only journal published monthly by the Japanese Society of Internal Medicine. Articles must be prepared in accordance with "The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Annals of Internal Medicine 108: 258-265, 1988), must be contributed solely to the Internal Medicine, and become the property of the Japanese Society of Internal Medicine. Statements contained therein are the responsibility of the author(s). The Society reserves copyright and renewal on all published material and such material may not be reproduced in any form without the written permission of the Society.